Researcher Dodged Questions on Ethics of Gene-Editing Experiment
Three weeks after news broke that the world’s first gene-edited babies had supposedly been born in China, questions still swirl around the success of the experiment, its ethics, and the scientist responsible.
Now, Caixin has found that China’s Clinical Trial Register rejected the experiment’s application due to holes in the informed-consent process and research design, as well as questions over trial implementation and funding.
Scientists have also cast new doubt on the effectiveness of the experiment, which lead researcher He Jiankui claims deleted genes from fetuses in an attempt to make them HIV-resistant.
On Nov. 26, He announced that he had removed genes from two human embryos before implanting them in their biological mother’s uterus. Resulting twin girls named Lulu and Nana were born early in November, he claimed. Outrage and near-universal condemnation followed.
At the International Summit on Human Genome Editing held in Hong Kong the same week, He presented his research and took questions from international experts. During his presentation, he admitted that the attempt to remove the CCR5 gene from Lulu’s DNA was unsuccessful.
However, beyond the violation of ethics, some gene-editing experts doubt whether the experiment will have the desired effect. A greater concern is the unknown consequences to the children involved. Lu Falong, a researcher from the Institute of Genetics and Developmental Biology at the Chinese Academy of Sciences, told Caixin that the attempt to edit Nana’s DNA may well have disabled the CCR5 gene. But the traits of the newly generated protein caused by the edit have never been studied before — and the result could not be predicted.
“This girl is like a little mouse being used to test the traits of the two new mutations of CCR5,” Lu said.
Hu Jinghua, a researcher at the Mayo Clinic who holds a doctorate in molecular development biology, published an article this month noting that He’s presentation did not indicate that the procedure had the desired effect on either embryo.
A search by Caixin of China’s publicly available Clinical Trial Register found that He and another researcher, Yan Jinzhou, had applied to register a trial titled “Evaluation of the Safety and Efficacy of Gene Editing with Human Embryo CCR5 gene.” The research implementation time was listed as March 7, 2017, to March 7, 2019, and the organizing institutions were the Southern University of Science and Technology and Shenzhen’s HarMoniCare Women and Children’s Hospital. Southern University of Science and Technology was listed as the “source of funds or materials.”
The application was rejected. On Nov. 8, the registration center notified He and Yan that their trial did not meet registration requirements. By Nov. 28, the researchers had still failed to provide necessary data to the registry and had not answered questions regarding the ethics review, informed-consent process, research design, trial implementation, and funding sources.
After the experiment became publicly known, the university and hospital both denied knowledge and involvement. Since Nov. 30, the trial’s status has been listed as “suspended or paused.”
According to the registry’s website, human trials must be registered before the first participant is recruited, and research information must be made public in a timely manner. But He had applied for registration only weeks before his experiment went public — long after he had recruited HIV-positive couples to participate.
While He’s experiment clearly violated the rules of the registry and appeared to breach health ministry guidelines on human-assisted reproduction and ministry-issued ethical guidelines, the punishment for violating such rules is unclear.
China’s National Health Commission and its provincial equivalent in Guangdong say they are investigating. Meanwhile, He has not appeared in public since the summit, at the end of November.
Contact reporter Ren Qiuyu (firstname.lastname@example.org)
- 1In Depth: Cash-Strapped Local Governments Turn to Financing Vehicles to Plug Fiscal Shortfalls
- 2Gallery: China’s Homegrown Jet Is Ready for Takeoff
- 3In Depth: Has China’s Monetary Policy Reached Its Limit?
- 4Weaker Demand for Chinese Goods Spells End of Shipping Boom
- 5Former Head of Exim Bank’s Beijing Branch Kicked Out of Communist Party
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas